• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[慢性心力衰竭的治疗]

[The therapy of chronic heart failure].

作者信息

Trenckmann H

机构信息

Klinik für Innere Medizin, Karl-Marx-Universität, Leipzig.

出版信息

Z Gesamte Inn Med. 1990 Jun 15;45(12):342-7.

PMID:2201131
Abstract

A rational therapy of the chronic cardiac insufficiency should be performed according to a certain scheme, in which case the knowledge of the basic disease is necessary for the causal treatment. Apart from the general measures the medicamentous therapy is of particular significance. Hereby up to now the digitalis glycosides remained the remedy of primary choice. They are without doubt indicated in the latent and manifest cardiac insufficiency, consequently from the transition of the NYHA stage II into stage III, in tachycardiac disturbances of rhythm also without cardiac insufficiency in form of auricular fibrillation and auricular flutter as well as in the paroxysmal supraventricular tachycardia. Prophylactic, preoperative applications of glycosides and such ones which are performed only for reasons of age are not justified. Also a maintenance therapy is in most cases no more necessary after removal of the cause of the cardiac insufficiency. - Diuretics are to be used in an insufficiency which continues existing despite application of glycosides. Their application must be performed as protracted as possible. - The therapies with vasodilators, such as prazosin, hydralazine and nitrates, which were performed during the last years, showed, indeed, initial success, but no long-term effect. Another fact it is, however, with the angiotensin-converting enzyme (ACE) inhibitors captopril and enalapril, which are to be regarded as second grade medicaments in combination with glycosides and diuretics. Whether or not they will supersede the glycosides, is at present still an open question. Other positively inotropic medicaments which in comparison to the glycosides show a larger therapeutic breadth are still being developed.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

慢性心功能不全的合理治疗应按照一定方案进行,在这种情况下,了解基础疾病对于病因治疗是必要的。除一般措施外,药物治疗具有特别重要的意义。迄今为止,洋地黄苷仍是首选药物。毫无疑问,它们适用于潜在和明显的心功能不全,即从纽约心脏病协会(NYHA)II级转变为III级时,也适用于无心力衰竭的快速心律失常,如心房颤动和心房扑动,以及阵发性室上性心动过速。预防性、术前使用洋地黄苷以及仅因年龄原因使用洋地黄苷是不合理的。而且在去除心功能不全的病因后,大多数情况下维持治疗也不再必要。——利尿剂应用于尽管使用洋地黄苷但仍持续存在的心功能不全。其应用必须尽可能持续进行。——过去几年使用的血管扩张剂,如哌唑嗪、肼屈嗪和硝酸盐类药物,确实显示出初步疗效,但没有长期效果。然而,对于血管紧张素转换酶(ACE)抑制剂卡托普利和依那普利,它们与洋地黄苷和利尿剂联合使用时被视为二线药物。它们是否会取代洋地黄苷,目前仍是一个悬而未决的问题。与洋地黄苷相比具有更大治疗范围的其他正性肌力药物仍在研发中。(摘要截取自250字)

相似文献

1
[The therapy of chronic heart failure].[慢性心力衰竭的治疗]
Z Gesamte Inn Med. 1990 Jun 15;45(12):342-7.
2
[Digitalis, diuretic and vasodilator treatment of cardiac failure].[洋地黄、利尿剂和血管扩张剂治疗心力衰竭]
Rev Prat. 1997 Dec 1;47(19):2125-9.
3
[The extension of heart failure therapy with vasodilators].
Z Gesamte Inn Med. 1990 Jun 15;45(12):352-6.
4
[The treatment of chronic cardiac decompensation].[慢性心脏代偿失调的治疗]
Ned Tijdschr Geneeskd. 1987 Apr 11;131(15):615-8.
5
[Acute and chronic cardiac decompensation: is vasodilator therapy useful?].[急性和慢性心功能不全:血管扩张剂治疗是否有效?]
Minerva Med. 1982 Jan 14;73(1-2):25-32.
6
[Therapy of chronic heart failure].[慢性心力衰竭的治疗]
Schweiz Rundsch Med Prax. 1992 May 19;81(21):696-703.
7
[Modern therapy of cardiac insufficiency].[现代心力衰竭治疗]
Med Pregl. 1999 Mar-May;52(3-5):113-24.
8
[Classic treatment of chronic heart insufficiency. What if new?].[慢性心力衰竭的经典治疗。新的治疗方法如何?]
Arch Mal Coeur Vaiss. 1995 Apr;88(4 Suppl):599-602.
9
[Therapy of dilated cardiomyopathy with digitalis, diuretics and vasodilators].[洋地黄、利尿剂及血管扩张剂治疗扩张型心肌病]
Herz. 1985 Jun;10(3):138-42.
10
[Therapy of heart failure. II. Therapy of chronic heart failure].
Fortschr Med. 1997 Jun 10;115(16):36-8, 41-5.